Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,709 GBX | +0.20% | +3.75% | +17.82% |
08:11am | GSK : Sell rating from JP Morgan | ZD |
02:17am | U.S. FDA approves Akebia's anemia drug | RE |
Chart calendar GSK plc
Upcoming events on GSK plc
Past events on GSK plc
2024-03-26 10:00 am | BNP Exane Healthcare Conference |
2024-03-19 09:00 am | Investor Meeting - ESG |
2024-03-18 | Berenberg UK Corporate Conference |
2024-03-06 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 02819 |
2024-03-06 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 03095 |
2024-03-06 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 01988 |
2024-03-06 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 03157 |
2024-03-06 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 03080 |
2024-03-06 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 00621 |
2024-03-06 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 01462 |
2024-03-06 02:51 pm | Retroviruses and Opportunistic Infection Conference - Poster No 03579 |
2024-03-05 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 01012 |
2024-03-05 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 03038 |
2024-03-05 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 02263 |
2024-03-05 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 01838 |
2024-03-05 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 01783 |
2024-03-05 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 03110 |
2024-03-05 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 02770 |
2024-03-05 12:00 pm | Retroviruses and Opportunistic Infection Conference - Poster No 03405 |
2024-03-04 04:30 pm | Retroviruses and Opportunistic Infection Conference - Poster No 02971 |
Past dividends on GSK plc
2024-02-21 | Final Payment 0.16 GBP |
2023-11-15 | Interim Payment 0.14 GBP |
2023-08-16 | Interim Payment 0.14 GBP |
2023-05-17 | Interim Payment 0.14 GBP |
2023-02-22 | Final Payment 0.1375 GBP |
2022-11-16 | Interim Payment 0.1375 GBP |
2022-08-17 | Interim Payment 0.1625 GBP |
2022-07-17 | 0 GBP |
2022-05-18 | Interim Payment 0.14 GBP |
2022-02-23 | Final Payment 0.23 GBP |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million GBP | Released Forecast Spread | 33 754 33 382 1.11% | 34 099 34 076 0.07% | 34 114 34 029 0.25% | 29 324 29 105 0.75% | 30 328 29 850 1.6% | 31 557 |
EBITDA Million GBP | Released Forecast Spread | 11 968 11 155 7.28% | 9 530 10 575 -9.88% | 11 330 10 048 12.76% | 10 449 9 257 12.88% | 11 635 10 203 14.04% | 10 736 |
EBIT Million GBP | Released Forecast Spread | 8 972 9 182 -2.29% | 8 906 8 955 -0.55% | 8 806 8 717 1.02% | 8 151 7 952 2.5% | 8 786 8 780 0.07% | 9 161 |
Earnings before Tax (EBT) Million GBP | Released Forecast Spread | 6 221 5 926 4.97% | 6 968 6 763 3.02% | 5 442 5 794 -6.07% | 5 628 5 548 1.45% | 6 064 7 498 -19.12% | 7 601 |
Net income Million GBP | Released Forecast Spread | 4 645 4 026 15.38% | 5 749 4 894 17.46% | 4 385 3 990 9.91% | 14 956 6 238 139.74% | 4 928 5 481 -10.09% | 5 604 |
EPS GBP | Released Forecast Spread | 1,16 1,06 9.69% | 1,43 1,21 17.91% | 1,08 1,02 6.28% | 3,66 1,66 120.52% | 1,22 1,38 -11.61% | 1,37 |
Announcement Date | 05/02/20 | 03/02/21 | 09/02/22 | 01/02/23 | 31/01/24 | - |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million GBP | Released Forecast Spread | 9 527 9 547 -0.21% | 9 780 9 145 6.94% | 6 929 6 906 0.33% | 7 829 7 214 8.52% | 7 376 7 101 3.88% | 6 951 6 580 5.64% | 7 178 6 795 5.63% | 8 147 7 727 5.43% | 8 052 7 621 5.65% | 7 091 | 7 612 | 8 371 | 8 169 |
EBITDA Million GBP | Released Forecast Spread | 2 406 2 392 0.58% | 3 317 2 850 16.4% | 2 639 2 138 23.45% | 3 561 2 704 31.68% | 1 602 1 855 -13.63% | 2 732 2 418 12.97% | 2 622 2 506 4.64% | 3 351 3 072 9.09% | 2 930 2 094 39.93% | 2 301 | 2 577 | 2 863 | 2 088 |
EBIT Million GBP | Released Forecast Spread | 1 893 1 885 0.41% | 2 613 2 291 14.06% | 2 008 1 740 15.4% | 2 605 2 264 15.08% | 1 595 1 509 5.7% | 2 092 1 930 8.42% | 2 170 1 999 8.56% | 2 772 2 570 7.88% | 1 752 1 836 -4.58% | 2 106 | 2 284 | 2 713 | 1 968 |
Earnings before Tax (EBT) Million GBP | Released Forecast Spread | 706 812 -13.05% | 2 598 2 268 14.55% | 896 1 243 -27.89% | 1 012 1 860 -45.59% | 1 626 946 71.97% | 1 907 1 529 24.72% | 1 987 1 500 32.51% | 1 791 2 225 -19.51% | 379 1 361 -72.15% | 1 721 | 1 803 | 2 431 | 1 525 |
Net income Million GBP | Released Forecast Spread | 749 122 515.71% | 1 802 1 674 7.66% | 975 802 21.54% | 10 315 1 356 660.76% | 1 495 1 151 29.9% | 1 490 1 179 26.41% | 1 624 1 213 33.86% | 1 464 1 739 -15.79% | 350 834 -58.04% | 1 396 | 1 523 | 1 905 | 825 |
EPS GBP | Released Forecast Spread | 0,18 0,09 106.69% | 0,45 0,41 8.83% | 0,21 0,21 -3.22% | 2,52 0,34 640.73% | 0,37 0,19 95.19% | 0,37 0,29 27.52% | 0,40 0,30 35.52% | 0,36 0,43 -15.26% | 0,09 0,20 -58.02% | 0,34 | 0,37 | 0,46 | 0,20 |
Announcement Date | 09/02/22 | 27/04/22 | 27/07/22 | 02/11/22 | 01/02/23 | 26/04/23 | 26/07/23 | 01/11/23 | 31/01/24 | - | - | - | - |
Past sector events for GSK plc
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock
- Equities
- Stock GSK plc - London S.E.
- Calendar GSK plc